André R Miserez1, Patrick Y Muller, Violeta Spaniol. 1. Cardiovascular Genetics, Institute of Biochemistry and Genetics, Department of Clinical-Biological Sciences, University of Basel, Basel, Switzerland.
Abstract
BACKGROUND: A syndrome characterized by hypertriglyceridaemia, hypercholesterolaemia, hyperinsulinaemia, and lipodystrophy has been found to be associated with highly active antiretroviral treatment (HAART) including protease inhibitors. A marker predicting this syndrome has been previously identified in the gene encoding the sterol-regulatory element-binding protein (SREBP)-1c, a regulator of triglycerides, cholesterol, insulin, and adipocytes. OBJECTIVE: A possible inhibition of SREBP-1c-dependent genes by the protease inhibitor indinavir and its possible reversal by the lipid-lowering drug simvastatin were studied. METHODS: The effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-dependent genes were compared with the effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-independent genes. RESULTS: Indinavir inhibited the SREBP-1c-dependent genes encoding the lipoprotein lipase (103 nmol/l resulted in an inhibition of 12.4%; P = 0.0051) and the fatty acid synthase (103 nmol/l resulted in an inhibition of 30.3%; P = 0.036) in a dose-dependent fashion but not the SREBP-1c-independent gene encoding the low-density lipoprotein receptor. Simvastatin antagonized the indinavir-induced SREBP-1c-inhibition. CONCLUSIONS: Indinavir inhibits important effector genes of the SREBP-1c pathway, explaining major HAART-related adverse effects.
BACKGROUND:A syndrome characterized by hypertriglyceridaemia, hypercholesterolaemia, hyperinsulinaemia, and lipodystrophy has been found to be associated with highly active antiretroviral treatment (HAART) including protease inhibitors. A marker predicting this syndrome has been previously identified in the gene encoding the sterol-regulatory element-binding protein (SREBP)-1c, a regulator of triglycerides, cholesterol, insulin, and adipocytes. OBJECTIVE: A possible inhibition of SREBP-1c-dependent genes by the protease inhibitor indinavir and its possible reversal by the lipid-lowering drug simvastatin were studied. METHODS: The effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-dependent genes were compared with the effects of indinavir and simvastatin on the inhibition/activation of SREBP-1c-independent genes. RESULTS:Indinavir inhibited the SREBP-1c-dependent genes encoding the lipoprotein lipase (103 nmol/l resulted in an inhibition of 12.4%; P = 0.0051) and the fatty acid synthase (103 nmol/l resulted in an inhibition of 30.3%; P = 0.036) in a dose-dependent fashion but not the SREBP-1c-independent gene encoding the low-density lipoprotein receptor. Simvastatin antagonized the indinavir-induced SREBP-1c-inhibition. CONCLUSIONS:Indinavir inhibits important effector genes of the SREBP-1c pathway, explaining major HAART-related adverse effects.
Authors: Juan Chaparro; Dominic N Reeds; Weidong Wen; E Xueping; Samuel Klein; Clay F Semenkovich; Kyongtae T Bae; Erin K Quirk; William G Powderly; Kevin E Yarasheski; Ellen Li Journal: Metabolism Date: 2005-05 Impact factor: 8.694
Authors: Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski Journal: World J Virol Date: 2015-05-12
Authors: W Todd Cade; Dominic N Reeds; Bettina Mittendorfer; Bruce W Patterson; William G Powderly; Samuel Klein; Kevin E Yarasheski Journal: Am J Physiol Endocrinol Metab Date: 2006-11-14 Impact factor: 4.310
Authors: Edilma M V Albuquerque; Eliana C de Faria; Helena C F Oliveira; Daniela O Magro; Lucia N Castilho Journal: BMC Infect Dis Date: 2005-06-14 Impact factor: 3.090